GHRP-2 10MG

GHRP-2 is a synthetic peptide analogous to the endogenous peptide ghrelin. Ghrelin is naturally occurring, first isolated from the stomach, composed of 28 amino acids, and helps regulate food intake, growth hormone release, and wound recovery. Growth hormone-releasing peptide GHRP 2 may induce the secretion of growth hormones (HGH) and may help maintain the required HGH concentrations. Bovine studies have suggested that GHRP-2 peptide exhibits multifaceted impacts; possibly acting on pituitary cells, stimulating secretion of GH, that it may bind with growth hormone release factor (GRF) receptor, may act on calcium channels, inducing secretion of calcium and GH release due to calcium influx, and, furthermore, may potentially stimulate cAMP pathway and protein kinase C. GHRP-2 has been researched for its potential binding activity, and may possibly stimulate adenyl cyclase activity. This may result in cAMP production and activation of protein kinase. Both elevated levels of cAMP and protein kinase may lead to increased calcium influx and subsequent growth hormone secretion.
 

GHRP-2 Peptide and GH Activity

This clinical study was conducted to understand the action of two synthetic GHRPs: GHRP-2 and Hexarelin (HEX) on growth hormones, prolactin, adrenocorticotropic hormone (ACTH) and cortisol concentrations. Two subject groups were studied – one, with six subjects aged between 22 and 27 years and the second, with six subjects aged between 66 and 73 years. Both groups were presented in positively correlated concentrations of both peptides. Researchers suggested there was a positive correlation between concentration and GH release in the subjects.

GHRP-2 Peptide and Appetite

In this clinical study, seven male subjects were divided into two groups, one of which was presented with GHRP-2 and the other with saline. They were then taken to a buffet meal to measure their food intake. It was reported by the researchers that the GHRP-2 subjects ate an average of 36% more than the saline subjects, with every subject reportedly exhibiting increased food intake when measured against their respective bodyweight. Furthermore, the GH levels also presented significant incremental increases in GHRP-2 subjects as compared to saline subjects.

GHRP-2 Peptide and GH Deficiency

The most common diagnostic tool for GH deficiency is the insulin tolerance test (ITT), which may cause contraindications. A clinical study aimed to explore the potential of GHRP-2 as a diagnostic resource for GH deficiency. The study reported 135 subjects who were first tested via ITT. Of these subjects, the study indicated 77 exhibited normal insulin tolerance and 58 exhibited GH peak levels of less than three. Post overnight fasting, all subjects were presented GHRP-2. After 2 hours, their blood samples were collected and tested. Upon analysis, it was reported by the researchers that the GH levels peaked after one hour of GHRP-2 in all subjects. These results were reportedly reproducible upon repetition of the tests. An additional clinical study was conducted to research the diagnostic properties of GHRP-2 on young subjects with GH deficiency (GHD) in comparison to the conventional compounds. 24 subjects with GHD were enrolled in this study. All subjects were presented with at least one conventional compound and later presented with GHRH and GHRP-2. All subjects were first given GHRP-2. When measured, the serum GH levels appeared significantly increased in these subjects. 21 subjects who demonstrated a robust response to the peptide were then presented with GHRP-2 and GHRH in combination. All subjects exhibited an apparent positive response in their GH levels, according to the researchers.

Combination Studies with TRH and GnRH

This clinical study was conducted on subjects with prolonged hypo-somatotropism, hypogonadism, or hypothyroid complications to evaluate the action of compounds of GHRP-2, Thyrotropin releasing hormone (TRH), and Gonadotropin releasing hormone (GnRH) with GHRP-2 alone and with GHRP-2 and TRH in combination. 33 male subjects were enrolled in the study. Over 5 days, 7 subjects were presented with a placebo, 9 subjects with GHRP-2 every hour, 9 subjects with GHRP-2 + TRH every hour, and the remainder subjects with GHRP-2 + TRH + GnRH every 90 minutes. Serum samples were collected on the first and last night of the study. After the results were analyzed, researchers suggested that the combination of GHRP-2 + GnRH + TRH induced the greatest apparent activation of growth hormones along thyroid stimulating hormone and luteinizing hormone axes, along with other possible metabolic effects. These actions were reported to be absent with GHRP-2 solo presentation and only partially seen with GHRP-2 and TRH combination.